Compare KBDC & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KBDC | PHAR |
|---|---|---|
| Founded | 2021 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 1.1B |
| IPO Year | 2018 | 2020 |
| Metric | KBDC | PHAR |
|---|---|---|
| Price | $13.66 | $15.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | $15.50 | ★ $38.00 |
| AVG Volume (30 Days) | ★ 402.7K | 19.0K |
| Earning Date | 06-04-2026 | 01-01-0001 |
| Dividend Yield | ★ 13.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $193.84 | $27.92 |
| Revenue Next Year | $9.00 | $8.86 |
| P/E Ratio | ★ $8.31 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.06 | $7.50 |
| 52 Week High | $16.98 | $21.34 |
| Indicator | KBDC | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 42.99 | 42.59 |
| Support Level | $13.54 | $12.98 |
| Resistance Level | $14.33 | $16.94 |
| Average True Range (ATR) | 0.36 | 0.63 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 50.60 | 19.57 |
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company that invests primarily in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through debt investments in middle-market companies.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.